AstraZeneca PLC (AZN)vsSomalogic Inc (SLGC)
AZN
AstraZeneca PLC
$185.95
-1.66%
HEALTHCARE · Cap: $282.69B
SLGC
Somalogic Inc
$9.91
0.00%
HEALTHCARE · Cap: $396.23M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 73855% more annual revenue ($60.44B vs $81.72M). AZN leads profitability with a 17.2% profit margin vs -159.5%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SLGC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SLGC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.7% — below average capital efficiency
Revenue declined 47.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SLGC
SLGC has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SLGC
The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while SLGC is a turnaround play — different risk/reward profiles.
SLGC carries more volatility with a beta of 1.64 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Somalogic Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
SomaLogic Inc. (SLGC) is a leading biotechnology firm revolutionizing the field of precision medicine through its proprietary SomaScan® platform, which specializes in protein biomarker discovery and analysis. Leveraging an extensive library of proteins, the company is dedicated to developing advanced diagnostics and therapeutic applications targeting critical health issues such as cancer, cardiovascular diseases, and metabolic disorders. Positioned at the forefront of the biomarker industry, SomaLogic not only drives innovation in both research and clinical environments but also forges strategic partnerships to broaden its impact and accelerate the adoption of its transformative technologies. With a commitment to data-driven health solutions, SomaLogic is focused on enhancing patient outcomes and tailoring therapeutic strategies to individual needs, making it a key player in the future of personalized medicine.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?